HC Wainwright Has Pessimistic Outlook of EBS Q2 Earnings

Emergent BioSolutions Inc. (NYSE:EBS - Free Report) - HC Wainwright lowered their Q2 2025 earnings estimates for Emergent BioSolutions in a report issued on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($0.26) per share for the quarter, down from their previous estimate of ($0.18). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Emergent BioSolutions' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions' Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.24 EPS and FY2026 earnings at $3.82 EPS.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.49 by $0.22. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The firm had revenue of $222.20 million for the quarter, compared to the consensus estimate of $218.50 million.

Separately, StockNews.com downgraded shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Price Performance

Emergent BioSolutions stock opened at $6.66 on Monday. The company has a market cap of $361.22 million, a price-to-earnings ratio of -1.62 and a beta of 2.09. The firm's fifty day moving average is $5.16 and its 200 day moving average is $7.78. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 52-week low of $4.02 and a 52-week high of $15.10.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Covestor Ltd increased its position in Emergent BioSolutions by 5,458.5% during the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 2,893 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Emergent BioSolutions in the fourth quarter worth about $63,000. E Fund Management Co. Ltd. bought a new position in shares of Emergent BioSolutions in the fourth quarter worth about $98,000. EP Wealth Advisors LLC bought a new position in shares of Emergent BioSolutions in the fourth quarter worth about $110,000. Finally, Alpine Global Management LLC bought a new position in shares of Emergent BioSolutions in the fourth quarter worth about $112,000. Institutional investors own 78.40% of the company's stock.

Insider Activity at Emergent BioSolutions

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at $589,413. The trade was a 25.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is owned by insiders.

Emergent BioSolutions declared that its board has approved a share buyback program on Monday, March 31st that authorizes the company to repurchase $50.00 million in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase up to 19% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.